Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
Dicerna Pharmaceuticals, Inc. (DRNA)
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.dicerna.com
Company Research
Source: Business Wire
– Collaboration to Explore Liver Cell Targets Using Dicerna’s GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates –– Each Company to Retain Rights to Co-Develop andCo-Commercialize Product Candidates –– Dicerna to Receive Upfront Payment of USD 175 Million andEquity Investment of USD 50 Million –– Dicerna is Eligible to Receive an Additional USD 75 Million Over the First Three Years, Plus Up to USD 357.5 Million per Target in Potential Milestone Payments, and Royalties on Product Sales –– Dicerna to Host Conference Call Today at 8:00 a.m. ET – LEXINGTON, Mass., & BAGSVÆRD, Denmark--(BUSINESS WIRE)--Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) and Novo Nordisk A/S today announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration plans to explore more than 30 liver cell targets and may deliver multiple
Show less
Read more
Impact Snapshot
Event Time:
DRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRNA alerts
High impacting Dicerna Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics